Clinical Trial: 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07914764) titled '68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis' on Oct. 29.

Brief Summary: Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.

Study Start Date: Aug. 01

Study Type: OBSERVATIONAL

Condition: Medullary Thyroid Carcinoma Small Cell Lung Cancer ( SCLC ) Gastric Adenocarcinoma

Intervention: DIAGNOSTIC_TEST: Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination

Intravenous injection of 68Ga-YQ-CC05 imaging agent, with a dos...